A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging

The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells

Inclusion Criteria:

• Patient must be 18 years of age or older at the time of signing the informed consent.
• Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer
• Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet.
• Men and women of child-producing potential, use of effective double barrier contraceptive methods during the study, up to 30 days after the last administration of the investigational product.
• Patient or legally authorized representative provided signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• Patient or legally authorized representative provided written authorization for use and disclosure of protected health information.

Exclusion Criteria:

• Pregnant or breastfeeding women
• Patients with a history of splenectomy or significant splenic dysfunction (e.g., as evidenced by splenomegaly or a history of recurrent infections due to impaired immune function)